Physician profile
Zehra Kapadia
NPI 1417930876
$6,489.73
in general payments reported to CMS, 2019-2025
64 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.69 · 2020: $112 · 2021: $11.92 · 2022: $815 · 2023: $1,769 · 2024: $2,101 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,179 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.94 |
| Education | $312.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $444.05 | 2022-2025 | |
| Pfizer INC. | $404.12 | 2022-2025 | |
| Janssen Biotech, INC. | $389.74 | 2022-2025 | Rybrevant, Erleada, Darzalex |
| Celgene Corporation | $378.64 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $369.15 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $352.46 | 2019-2025 | Opdivo, Opdualag |
| Tempus Ai, INC | $330.25 | 2024-2025 | Xt Cdx |
| Eisai INC. | $257.12 | 2022-2025 | |
| Genzyme Corporation | $230.70 | 2022-2023 | |
| Astellas Pharma US INC | $222.18 | 2022-2025 | Xtandi, Xospata, Vyloy |
| Astrazeneca Pharmaceuticals LP | $182.81 | 2022-2025 | Enhertu, Imfinzi |
| Array Biopharma INC | $149.54 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $147.30 | 2021-2025 | Trodelvy |
| Seagen INC. | $144.04 | 2020-2023 | Adcetris, Padcev |
| Rigel Pharmaceuticals, INC. | $138.69 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $134.74 | 2023-2025 | |
| Sobi, INC | $117.23 | 2023-2024 | |
| Amgen INC. | $116.92 | 2022-2024 | Lumakras, Nplate, Xgeva |
| Merck Sharp & Dohme LLC | $111.87 | 2023-2025 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $94.46 | 2024-2025 | Ojjaara, Blenrep |
| Stemline Therapeutics INC. | $92.66 | 2023-2025 | Orserdu |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Beigene USA, INC. | $87.82 | 2023-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $86.13 | 2023-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $79.63 | 2022-2025 | |
| Tactile Systems Technology INC | $73.21 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Springworks Therapeutics, INC. | $68.50 | 2024-2025 | Ogsiveo, Gomekli |
| Pharmacyclics LLC, An Abbvie Company | $64.98 | 2022-2023 | Imbruvica |
| Morphosys, US INC. | $62.51 | 2022-2023 | Monjuvi |
| Fennec Pharmaceuticals, INC. | $60.12 | 2023-2024 | Pedmark |
| Beone Medicines USA, INC. | $56.70 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $56.49 | 2022-2023 | Vonjo |
| Genentech USA, INC. | $53.52 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Incyte Corporation | $52.96 | 2023-2024 | Monjuvi, Jakafi |
| Taiho Oncology, INC. | $52.34 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $49.08 | 2022-2024 | Qinlock |
| Abbvie INC. | $48.49 | 2023-2024 | |
| Lilly USA, LLC | $41.14 | 2022 | |
| Puma Biotechnology, INC. | $38.20 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $36.87 | 2025 | Pyrukynd |
| Kyowa Kirin, INC. | $35.87 | 2023 | Poteligeo |
| Ipsen Biopharmaceuticals, INC | $34.29 | 2024 | Onivyde |
| Immunocore Limited | $32.26 | 2025 | Kimmtrak |
| Karyopharm Therapeutics INC. | $31.73 | 2023-2024 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.32 | 2019 | |
| Blueprint Medicines Corporation | $26.70 | 2025 | Ayvakit |
| Emd Serono, INC. | $23.81 | 2023 | Tepmetko |
| Inari Medical, INC. | $23.42 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Apellis Pharmaceuticals, INC. | $23.09 | 2022 | |
| Pharmacosmos Therapeutics INC. | $22.07 | 2023 | Monoferric |
| Dendreon Pharmaceuticals LLC | $21.49 | 2024 | Provenge |
| Sumitomo Pharma America, INC. | $20.85 | 2023 | Orgovyx |
| Shield Therapeutics INC | $20.76 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.45 | 2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $19.54 | 2023 | Clonoseq |
| Tersera Therapeutics LLC | $19.52 | 2025 | Xermelo |
| Genmab U.S., INC. | $18.82 | 2024 | Epkinly |
| Sun Pharmaceutical Industries INC. | $18.70 | 2023 | Odomzo, Yonsa |
| Pharming Healthcare, INC. | $17.91 | 2024 | Ruconest |
| Amneal Pharmaceuticals LLC | $17.09 | 2025 | Alymsys |
| Sirtex Medical INC | $15.69 | 2023 | Sir-Spheres Microspheres |
| Clovis Oncology, INC. | $14.40 | 2019 | |
| Aveo Pharmaceuticals, INC. | $13.38 | 2023 | Fotivda |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zehra Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.